Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

G1 Therapeutics Stock

Price
Target price
€2.38

€2.38

0.610%
0.014
0.610%
€8.39
 
03.07.24 / Tradegate WKN: A2DR0J / Symbol: GTHX / Name: G1 Therapeutics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of G1 Therapeutics in the next few years
Wizard

Description G1 Therapeutics

G1 Therapeutics is a clinical-stage biopharmaceutical company that is focused on the discovery, development, and commercialization of novel cancer treatments. The company's lead drug candidate, Trilaciclib, is a CDK4/6 inhibitor that is being developed for the treatment of small cell lung cancer (SCLC), which is a type of lung cancer that is aggressive and has a poor prognosis. Trilaciclib is designed to protect bone marrow from the toxic effects of chemotherapy and improve patient outcomes. The company is also developing other drug candidates for the treatment of various types of cancer. G1 Therapeutics went public in May 2017 and is listed on the NASDAQ stock exchange under the symbol GTHX. As of August 2021, the company has a market capitalization of approximately $1.3 billion.

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock G1 Therapeutics is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for G1 Therapeutics

sharewise wants to provide you with the best news and tools for G1 Therapeutics, so we directly link to the best financial data sources.

Financials

News

Broker